Patents by Inventor Felix Unverdorben

Felix Unverdorben has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210101975
    Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel engineered T cell receptor (TCR) based molecules which are selective and specific for the tumor expressing antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
    Type: Application
    Filed: December 17, 2020
    Publication date: April 8, 2021
    Inventors: Felix UNVERDORBEN, Sebastian BUNK, Martin HOFMANN, Dominik MAURER, Meike HUTT, Claudia WAGNER, Leonie ALTEN
  • Publication number: 20210048442
    Abstract: The present invention relates to a method for the characterization of peptide:MHC binding polypeptides, e.g. by mass spectrometry and an analysis of the recognized peptide space, i.e. in order to identify peptides that can be bound in the context of their presentation by MHC, and those who cannot be bound.
    Type: Application
    Filed: August 11, 2020
    Publication date: February 18, 2021
    Inventors: Heiko SCHUSTER, Meike HUTT, Toni WEINSCHENK, Sebastian BUNK, Oliver SCHOOR, Linus BACKERT, Martin HOFMANN, Jens FRITSCHE, Felix UNVERDORBEN, Gisela SCHIMMACK, Florian SALOPIATA
  • Publication number: 20210032361
    Abstract: The present invention concerns antigen binding proteins specifically binding melanoma associated antigen A (MAGE-A) protein-derived antigens. The invention in particular provides antigen binding proteins which specifically bind to the MAGE-A antigenic peptide comprising or consisting of SEQ ID NO: 1 in a complex with a major histocombatibility (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said MAGE-A peptide/MHC complex. The antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of MAGE-A expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.
    Type: Application
    Filed: July 30, 2020
    Publication date: February 4, 2021
    Inventors: Meike HUTT, Felix UNVERDORBEN, Sebastian BUNK, Dominik MAURER, Martin HOFMANN, Gabriele PSZOLLA, Sara YOUSEF, Claudia WAGNER, Frank SCHWOEBEL, Heiko SCHUSTER
  • Publication number: 20210032370
    Abstract: The present invention concerns bispecific antigen binding proteins directed against MHC presented target antigens (TA). The invention in particular provides bispecific antigen binding proteins comprising at least two antigen binding sites (A and B), wherein the antigen binding site A binds to CD3 and the antigen binding site B binds to a target antigenic (TA) peptide/MHC complex. The bispecific antigen binding proteins of the invention comprise, in particular, the CDRs of the VL and VH domains of novel engineered anti-CD3 antibodies having a reduced affinity. The bispecific antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of TA associated diseases, such as tumor-associated antigen (TAA) expressing cancerous diseases.
    Type: Application
    Filed: July 30, 2020
    Publication date: February 4, 2021
    Inventors: Gabriele PSZOLLA, Martin HOFMANN, Felix UNVERDORBEN, Meike HUTT, Dominik MAURER, Sebastian BUNK
  • Patent number: 10889645
    Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel engineered T cell receptor (TCR) based molecules which are selective and specific for the tumor expressing antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
    Type: Grant
    Filed: January 7, 2020
    Date of Patent: January 12, 2021
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Felix Unverdorben, Sebastian Bunk, Martin Hofmann, Dominik Maurer, Meike Hutt, Claudia Wagner, Leonie Alten
  • Publication number: 20200263162
    Abstract: The present invention relates to improved yeast transformation of yeast cells and yeast cell libraries transformed thereby. More specifically, the present invention relates to the transformation of yeast by electroporation.
    Type: Application
    Filed: May 8, 2020
    Publication date: August 20, 2020
    Inventors: Sebastian BUNK, Dominik MAURER, Felix UNVERDORBEN
  • Publication number: 20200207849
    Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel engineered T cell receptor (TCR) based molecules which are selective and specific for the tumor expressing antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
    Type: Application
    Filed: January 7, 2020
    Publication date: July 2, 2020
    Inventors: Felix UNVERDORBEN, Sebastian BUNK, Martin HOFMANN, Dominik MAURER, Meike HUTT, Claudia WAGNER, Leonie ALTEN
  • Patent number: 10683495
    Abstract: The present invention relates to improved yeast transformation of yeast cells and yeast cell libraries transformed thereby. More specifically, the present invention relates to the transformation of yeast by electroporation.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: June 16, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Sebastian Bunk, Dominik Maurer, Felix Unverdorben
  • Patent number: 10618956
    Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel engineered T cell receptor (TCR) based molecules which are selective and specific for the tumor expressing antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: April 14, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Felix Unverdorben, Sebastian Bunk, Martin Hofmann, Dominik Maurer, Meike Hutt, Claudia Wagner, Leonie Alten
  • Patent number: 10428120
    Abstract: The present invention relates to complexes comprising (i) an immunoglobulin (Ig) binding moiety and (ii) a pharmaceutically active moiety, wherein the Ig binding moiety specifically binds to the constant domain 1 of the heavy chain (CH1) of an Ig molecule and their use for therapy and prophylaxis.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: October 1, 2019
    Assignee: UNIVERSITAT STUTTGART
    Inventors: Roland Kontermann, Felix Unverdorben, Meike Hutt
  • Publication number: 20190135914
    Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel engineered T cell receptor (TCR) based molecules which are selective and specific for the tumor expressing antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
    Type: Application
    Filed: November 5, 2018
    Publication date: May 9, 2019
    Inventors: Felix UNVERDORBEN, Sebastian BUNK, Martin HOFMANN, Dominik MAURER, Meike HUTT, Claudia WAGNER, Leonie ALTEN
  • Publication number: 20190016801
    Abstract: The present invention relates to a bispecific polypeptide molecule comprising a first polypeptide chain and a second polypeptide chain providing a binding region derived from a T cell receptor (TCR) being specific for a major histocompatibility complex (MHC)-associated peptide epitope, and a binding region derived from an antibody capable of recruiting human immune effector cells by specifically binding to a surface antigen of said cells, as well as methods of making the bispecific polypeptide molecule, and uses thereof.
    Type: Application
    Filed: July 13, 2018
    Publication date: January 17, 2019
    Inventors: Martin HOFMANN, Felix UNVERDORBEN, Sebastian BUNK, Dominik MAURER
  • Publication number: 20190016804
    Abstract: The present invention relates to a bispecific polypeptide molecule comprising a first polypeptide chain and a second polypeptide chain providing a binding region derived from a T cell receptor (TCR) being specific for a major histocompatibility complex (MHC)-associated viral peptide epitope, and a binding region derived from an antibody capable of recruiting human immune effector cells by specifically binding to a surface antigen of said cells, as well as methods of making the bispecific polypeptide molecule, and uses thereof.
    Type: Application
    Filed: July 13, 2018
    Publication date: January 17, 2019
    Inventors: Martin HOFMANN, Felix UNVERDORBEN, Sebastian BUNK, Dominik MAURER
  • Publication number: 20190016803
    Abstract: The present invention relates to a bispecific polypeptide molecule comprising a first polypeptide chain and a second polypeptide chain providing a binding region derived from a T cell receptor (TCR) being specific for a major histocompatibility complex (MHC)-associated peptide epitope, and a binding region derived from an antibody capable of recruiting human immune effector cells by specifically binding to a surface antigen of said cells, as well as methods of making the bispecific polypeptide molecule, and uses thereof.
    Type: Application
    Filed: July 13, 2018
    Publication date: January 17, 2019
    Inventors: Martin Hofmann, Felix Unverdorben, Sebastian Bunk, Dominik Maurer
  • Publication number: 20190016802
    Abstract: The present invention relates to a bispecific polypeptide molecule comprising a first polypeptide chain and a second polypeptide chain providing a binding region derived from a T cell receptor (TCR) being specific for a major histocompatibility complex (MHC)-associated peptide epitope, and a binding region derived from an antibody capable of recruiting human immune effector cells by specifically binding to a surface antigen of said cells, as well as methods of making the bispecific polypeptide molecule, and uses thereof.
    Type: Application
    Filed: July 13, 2018
    Publication date: January 17, 2019
    Inventors: Martin HOFMANN, Felix UNVERDORBEN, Sebastian BUNK, Dominik MAURER
  • Publication number: 20180135039
    Abstract: The present invention relates to improved yeast transformation of yeast cells and yeast cell libraries transformed thereby. More specifically, the present invention relates to the transformation of yeast by electroporation.
    Type: Application
    Filed: November 15, 2017
    Publication date: May 17, 2018
    Inventors: Sebastian BUNK, Dominik MAURER, Felix UNVERDORBEN
  • Publication number: 20170145062
    Abstract: The present invention relates to complexes comprising (i) an immunoglobulin (Ig) binding moiety and (ii) a pharmaceutically active moiety, wherein the Ig binding moiety specifically binds to the constant domain 1 of the heavy chain (CH1) of an Ig molecule and their use for therapy and prophylaxis.
    Type: Application
    Filed: January 19, 2017
    Publication date: May 25, 2017
    Inventors: Roland Kontermann, Felix Unverdorben, Meike Hutt
  • Publication number: 20140220017
    Abstract: The present invention relates to complexes comprising (i) an immunoglobulin (Ig) binding moiety and (ii) a pharmaceutically active moiety, wherein the Ig binding moiety specifically binds to the constant domain 1 of the heavy chain (CH1) of an Ig molecule and their use for therapy and prophylaxis.
    Type: Application
    Filed: September 24, 2012
    Publication date: August 7, 2014
    Inventors: Roland Kontermann, Felix Unverdorben, Meike Hutt